New insights into medicines for preeclampsia


Burnet Institute researchers have led the development of the first global strategic guidelines—called target product profiles (TPPs)—for medicines to prevent and treat preeclampsia, a hypertensive disorder in pregnancy that’s one of the leading causes of maternal deaths, stillbirth, and preterm birth globally.

IVF patients need personally tailored support from doctors to make informed choices

Previous article

Not super creative? Try this approach

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations